John Burn

List of Publications by Year in descending order

55 papers	16,044 citations	41344 49 h-index	155660 55 g-index
55 all docs	55 docs citations	55 times ranked	21110 citing authors

#	Article	IF	Citations
1	Prevalence and architecture of de novo mutations in developmental disorders. Nature, 2017, 542, 433-438.	27.8	1,211
2	Large-scale discovery of novel genetic causes of developmental disorders. Nature, 2015, 519, 223-228.	27.8	998
3	Celecoxib for the Prevention of Sporadic Colorectal Adenomas. New England Journal of Medicine, 2006, 355, 873-884.	27.0	964
4	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, The, 2011, 378, 2081-2087.	13.7	849
5	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncology, The, 2009, 10, 501-507.	10.7	642
6	Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genetics, 2000, 25, 160-165.	21.4	640
7	Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut, 2010, 59, 975-986.	12.1	635
8	Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.	12.1	630
9	Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut, 2008, 57, 704-713.	12.1	591
10	Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nature Genetics, 2001, 28, 350-354.	21.4	533
11	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of Medical Genetics, 2007, 44, 353-362.	3.2	461
12	Endoglin, an Ancillary TGFÎ² Receptor, Is Required for Extraembryonic Angiogenesis and Plays a Key Role in Heart Development. Developmental Biology, 2000, 217, 42-53.	2.0	418
13	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	12.1	411
14	Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	12.1	410
15	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
16	Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. Lancet, The, 1998, 351, 311-316.	13.7	345
17	Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. PLoS Genetics, 2010, 6, e1000899.	3.5	331
18	Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nature Genetics, 2003, 34, 403-412.	21.4	310

#	Article	IF	Citations
19	Estimates of benefits and harms of prophylactic use of aspirin in the general population. Annals of Oncology, 2015, 26, 47-57.	1.2	303
20	A homeobox gene, HLXB9, is the major locus for dominantly inherited sacral agenesis. Nature Genetics, 1998, 20, 358-361.	21.4	287
21	Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine, 2008, 359, 2567-2578.	27.0	273
22	Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nature Genetics, 2000, 25, 42-46.	21.4	252
23	European Code Against Cancer and scientific justification: third version (2003). Annals of Oncology, 2003, 14, 973-1005.	1.2	247
24	Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview. Cancer Prevention Research, 2012, 5, 164-178.	1.5	242
25	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863.	13.7	220
26	Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype.. Journal of Medical Genetics, 1998, 35, 558-565.	3.2	205
27	Molecular Analysis of Hereditary Nonpolyposis Colorectal Cancer in the United States: High Mutation Detection Rate among Clinically Selected Families and Characterization of an American Founder Genomic Deletion of the MSH2 Gene. American Journal of Human Genetics, 2003, 72, 1088-1100.	6.2	195
28	A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. Cancer Prevention Research, 2011, 4, 655-665.	1.5	193
29	Autosomal dominant sacral agenesis: Currarino syndrome. Journal of Medical Genetics, 2000, 37, 561-566.	3.2	186
30	The CHEK2 1100delC Mutation Identifies Families with a Hereditary Breast and Colorectal Cancer Phenotype. American Journal of Human Genetics, 2003, 72, 1308-1314.	6.2	185
31	Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain, 2006, 130, 110-119.	7.6	178
32	Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research, 2009, 2, 310-321.	1.5	176
33	Genomic deletions inMSH2 orMLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: Identification of novel and recurrent deletions by MLPA. Human Mutation, 2003, 22, 428-433.	2.5	154
34	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153
35	A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nature Genetics, 2000, 26, 362-364.	21.4	152
36	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	3.5	148

#	Article	IF	Citations
37	Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. Journal of Allergy and Clinical Immunology, 2013, 132, 1121-1129.	2.9	135
38	Behavioural phenotype of Cornelia de Lange syndrome. Archives of Disease in Childhood, 1999, 81, 333-336.	1.9	129
39	Three molecular pathways model colorectal carcinogenesis in <scp>L</scp>ynch syndrome. International Journal of Cancer, 2018, 143, 139-150.	5.1	129
40	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	12.1	127
41	Mouse Model for Hereditary Hemorrhagic Telangiectasia Has a Generalized Vascular Abnormality. Circulation, 2003, 107, 1653-1657.	1.6	119
42	Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes and Cancer, 2005, 44, 123-138.	2.8	112
43	A Mutation Hot Spot for Nonspecific X-Linked Mental Retardation in the MECP2 Gene Causes the PPM-X Syndrome. American Journal of Human Genetics, 2002, 70, 1034-1037.	6.2	111
44	Twenty-year trends in prevalence and survival of Down syndrome. European Journal of Human Genetics, 2008, 16, 1336-1340.	2.8	110
45	Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Coxâ€• independent mechanism. FASEB Journal, 2006, 20, 2009-2016.	0.5	103
46	Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Nature Genetics, 2007, 39, 963-965.	21.4	103
47	Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Familial Cancer, 2010, 9, 109-115.	1.9	103
48	Low erythrocyte folate status and polymorphic variation in folate-related genes are associated with risk of neural tube defect pregnancy. Molecular Genetics and Metabolism, 2004, 81, 273-281.	1.1	88
49	A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics. British Journal of Cancer, 2001, 85, 166-170.	6.4	78
50	Clinical features associated with CTNNB1 de novo loss of function mutations in ten individuals. European Journal of Medical Genetics, 2017, 60, 130-135.	1.3	47
51	How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies. Cancers, 2021, 13, 406.	3.7	31
52	The rise of point-of-care genetics: how the SARS-CoV-2 pandemic will accelerate adoption of genetic testing in the acute setting. European Journal of Human Genetics, 2021, 29, 891-893.	2.8	12
53	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
54	Sebaceous tumours: a prototypical class of skin tumour for universal germline genetic testing. British Journal of Dermatology, 2021, 185, 1045-1046.	1.5	2

#	Article	IF	Citations
55	Response to â€˜Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndromeâ€associated tumoursâ€™. British Journal of Dermatology, 2022, , .	1.5	1